Core Viewpoint - Bidu Pharmaceutical (688073.SH) announced a share reduction plan by its shareholders due to liquidity needs, involving a total of up to 336,000 shares, which represents approximately 2.6% of the company's total share capital [1] Group 1: Shareholder Reduction Plans - Shareholder Xinxin Management plans to reduce its holdings by up to 1.14% of the total share capital through block trades and 0.40% through centralized bidding [1] - Shareholder Landan Management intends to reduce its holdings by up to 0.86% through block trades and 0.40% through centralized bidding [1] - Shareholder Wu Bo plans to reduce his holdings by up to 0.20% through centralized bidding [1]

Core Viewpoint - Bidu Pharmaceutical (688073.SH) announced a share reduction plan by its shareholders due to liquidity needs, involving a total of up to 336,000 shares, which represents approximately 2.6% of the company's total share capital [1] Group 1: Shareholder Reduction Plans - Shareholder Xinxin Management plans to reduce its holdings by up to 1.14% of the total share capital through block trades and 0.40% through centralized bidding [1] - Shareholder Landan Management intends to reduce its holdings by up to 0.86% through block trades and 0.40% through centralized bidding [1] - Shareholder Wu Bo plans to reduce his holdings by up to 0.20% through centralized bidding [1]

Core Viewpoint - Bid Pharma (688073.SH) announced a share reduction plan by its shareholders due to personal liquidity needs, involving multiple parties and specific share quantities to be sold through different trading methods [1] Shareholder Reduction Plan - Shareholder Xinxin Management plans to reduce its holdings by up to 1,036,065 shares through block trading, representing 1.14% of the total share capital, and up to 363,532 shares through centralized bidding, representing 0.40% of the total share capital [1] - Shareholder Landan Management intends to reduce its holdings by up to 781,593 shares through block trading, representing 0.86% of the total share capital, and up to 363,532 shares through centralized bidding, also representing 0.40% of the total share capital [1] - Shareholder Wu Bo plans to reduce his holdings by up to 181,766 shares through centralized bidding, representing 0.20% of the total share capital [1]

证券代码：688073 证券简称：毕得医药 公告编号：2026-003 上海毕得医药科技股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 欣曦管理、兰旦管理所持股份来源为公司首次公开发行并上市前取得的股份 及公司权益分派由资本公积转增股本方式取得的股份，吴波本次拟减持的股份系 公司原股东宁波鼎华永创创业投资合伙企业（有限合伙）（以下简称"鼎华永创"） 解散后，通过证券非交易过户的方式取得。 大股东持有的基本情况 截至本公告披露日，上海毕得医药科技股份有限公司（以下简称"毕得医药" 或"公司"）股东舟山欣曦企业管理合伙企业（有限合伙）（以下简称"欣曦管理"） 持有公司无限售条件流通股 4,717,881 股，占公司股份总数的 5.19%。股东舟山 兰旦企业管理合伙企业（有限合伙）（以下简称"兰旦管理"）持有公司股份 3,584,615 股，占公司股份总数的 3.94%，其中 69,486 股为有限售条件流通股， 3,515,129 股为无限售条件流通股。股东吴波持 ...

Core Viewpoint - Bid Pharma (688073.SH) announced a share reduction plan by its shareholders due to personal liquidity needs, involving multiple parties and specific share quantities to be sold through different trading methods [1] Group 1: Shareholder Reduction Plans - Shareholder Xinxin Management plans to reduce its holdings by up to 1,036,065 shares through block trading, representing 1.14% of the total share capital, and up to 363,532 shares through centralized bidding, representing 0.40% of the total share capital [1] - Shareholder Landan Management intends to reduce its holdings by up to 781,593 shares through block trading, representing 0.86% of the total share capital, and up to 363,532 shares through centralized bidding, also representing 0.40% of the total share capital [1] - Shareholder Wu Bo plans to reduce his holdings by up to 181,766 shares through centralized bidding, representing 0.20% of the total share capital [1]

Core Viewpoint - The announcement from Bid Pharma indicates that shareholders Xinxin Management, Landan Management, and Wu Bo plan to reduce their holdings by up to 3.00% within three months after the disclosure date, primarily due to funding needs [1] Shareholder Reduction Plans - Xinxin Management intends to reduce its holdings through block trading by up to 1.14% and through centralized bidding by up to 0.40% [1] - Landan Management plans to reduce its holdings through block trading by up to 0.86% and through centralized bidding by up to 0.40% [1] - Wu Bo aims to reduce his holdings through centralized bidding by up to 0.20% [1] Impact on Company - The reduction in shareholding is not expected to have a significant impact on the company's governance structure, ownership structure, or ongoing operations [1]

证券代码：688073 证券简称：毕得医药 公告编号：2026-001 上海毕得医药科技股份有限公司 关于补充确认 2025 年度日常关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2、董事会审计委员会审议情况 公司于 2025 年 12 月 31 日召开第二届董事会审计委员会第十二次会议决议， 审议通过了《关于补充确认 2025 年度日常关联交易的议案》，董事会审计委员会 认为：公司补充确认的日常关联交易是为了满足业务发展及生产经营的需要，系 公司日常经营过程中发生的持续性交易行为，具有商业合理性。日常关联交易定 价政策和定价依据遵照公开、公平、公正的原则，双方交易价格按照市场价格结 算，不会对公司及公司财务状况、经营成果产生不利影响，不存在损害公司及全 体股东特别是中小股东利益的行为。同意本次关联交易事项，并同意将该事项提 交公司董事会审议。 重要内容提示： 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 1、独立董事专门会议审议情况 公司于 2025 年 12 月 31 日召开第二届董事会 ...

证券代码：688073 证券简称：毕得医药 公告编号：2026-002 上海毕得医药科技股份有限公司 关于 2025 年半年度报告的更正公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海毕得医药科技股份有限公司（以下简称"公司"）披露的《2025 年半年 度报告》，经事后核查，未准确填报关联方及关联交易情况。公司董事会及管理 层高度重视，第一时间组织财务人员进一步核查及确认，并对相关数据予以更正， 具体更正信息如下： 一、更正内容 1、"第八节财务报告"之"十四、关联方及关联交易"之"4、其他关联方 情况"。 更正前： [注 1]2025 年 1 月 8 日，公司召开第二届董事会第十四次会议，审议通过了《关于聘任公司高级 管理人员的议案》《关于补选公司第二届董事会非独立董事的议案》，同意聘任张锐豪先生为公司 副总经理，任期自董事会审议通过之日起至第二届董事会任期届满之日止；并同意提名张锐豪先 生为公司第二届董事会非独立董事候选人，任期自股东大会审议通过之日起至第二届董事会任期 届满之日止。 更正后： | 其他关联方 ...

国泰海通证券股份有限公司 关于上海毕得医药科技股份有限公司 补充确认2025年度日常关联交易的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"）作为 上海毕得医药科技股份有限公司（以下简称"毕得医药"或"公司"）首次公开 发行股票并在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》 《上海证券交易所科创板股票上市规则》《上海证券交易所科创板上市公司自律 监管指引第 1 号——规范运作》等相关法律、法规和规范性文件的规定，对毕 得医药 2025 年度日常关联交易的事项进行了专项核查，核查情况与意见如下： 一、日常关联交易基本情况 （一）基本情况概述 公司 2025 年度向关联方西格莱购买原材料、销售商品、采购设备，发生关 联交易的合计金额为 554.91 万元人民币，其中购买原材料 0.93 万元，销售商品 460.18万元，采购设备 93.80万元。2024年度，公司与西格莱发生关联交易的金 额为 592.27 万元人民币。 Liangfu Huang 自 2025 年 1 月 1 日起向公司提供咨询服务，发生关联交易的 金额为 24.00 万美元。公司拟根据其 2025 年度 ...

Group 1 - The core business of Shanghai Bid Pharmaceutical Technology Co., Ltd. focuses on the front end of new drug research and development, providing innovative drug molecular building blocks and scientific reagents [2] - As of September 30, 2025, the company achieved operating revenue of 979 million yuan, a year-on-year increase of 20.67%, and a net profit attributable to shareholders of 120 million yuan, up 42.79% year-on-year [2] - The company has distributed a total of 258 million yuan in dividends since its A-share listing [3] Group 2 - On December 31, Bid Pharmaceutical's stock rose by 0.66%, with a trading volume of 59.01 million yuan [1] - The financing buy-in amount on December 31 was 2.45 million yuan, while the financing repayment was 4.40 million yuan, resulting in a net financing buy-in of -1.95 million yuan [1] - The total balance of margin trading as of December 31 was 33.48 million yuan, accounting for 1.27% of the circulating market value, which is below the 30th percentile level over the past year [1]